Sugi Predict

Sugi Predict / Targets / PDCD1

PDCD1

Programmed cell death protein 1 · Q15116 · PDCD1 on Sugi Atlas →

113,434 patent compounds predicted against PDCD1, 67,983 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL565483 SCHEMBL565483 0.44 12/20
Bromide Bromide (SCHEMBL437878) 0.54 10/20
SCHEMBL407298 SCHEMBL407298 0.54 9/20
Bromide Bromide (SCHEMBL439705) 0.53 9/20
SCHEMBL565419 SCHEMBL565419 0.44 9/20
SCHEMBL565274 SCHEMBL565274 0.40 9/20
SCHEMBL565267 SCHEMBL565267 0.40 9/20
SCHEMBL310937 SCHEMBL310937 0.53 8/20
SCHEMBL373611 SCHEMBL373611 0.51 8/20
SCHEMBL373612 SCHEMBL373612 0.51 8/20
SCHEMBL373613 SCHEMBL373613 0.51 8/20
SCHEMBL437167 SCHEMBL437167 0.49 8/20
SCHEMBL565172 SCHEMBL565172 0.38 8/20
SCHEMBL410123 SCHEMBL410123 0.46 7/20
SCHEMBL247192 SCHEMBL247192 0.46 7/20
SCHEMBL565164 SCHEMBL565164 0.43 7/20
SCHEMBL565160 SCHEMBL565160 0.41 7/20
SCHEMBL564976 SCHEMBL564976 0.40 7/20
SCHEMBL373245 SCHEMBL373245 0.56 6/20
SCHEMBL373246 SCHEMBL373246 0.56 6/20

Clinical trials — most relevant to PDCD1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria PHASE4RECRUITING
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma PHASE3COMPLETED
Effect of Tramadol Versus Morphine on PD1 and PD1-ligand in Patients With Chronic Cancer Pain PHASE2/PHASE3UNKNOWN
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer PHASE2RECRUITING
Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer PHASE2UNKNOWN
Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer PHASE2COMPLETED
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation PHASE2UNKNOWN
PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC PHASE1/PHASE2COMPLETED
Pembrolizumab + Poly-ICLC in MRP Colon Cancer PHASE1/PHASE2COMPLETED
PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer PHASE2ACTIVE_NOT_RECRUITING
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer PHASE2ACTIVE_NOT_RECRUITING
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary PHASE2UNKNOWN
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide PHASE2COMPLETED
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC PHASE2COMPLETED
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease PHASE2COMPLETED
Neoadjuvant Atezolizumab in Localized Bladder Cancer PHASE2COMPLETED
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype PHASE2ACTIVE_NOT_RECRUITING
TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer PHASE2UNKNOWN
MPDL3280A-treatment-IST-UMCG PHASE2UNKNOWN
A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors PHASE1COMPLETED
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma PHASE1COMPLETED
Effect of Severe Trauma on PD1 and Its Legend (PD1/L1) on T Lymphocytes and Correlation With Mortality nanUNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Role of Programmed Death Ligand 1 in Colorectal Cancer nanNOT_YET_RECRUITING
Immune Checkpoints in Intraabdominal Ascites Fluid nanCOMPLETED
Effect of Anesthesia on Expression of Programmed Death-1 and Programmed Death-1 Ligand in Breast Cancer nanUNKNOWN
Analysis of the Microenvironment of Lung Cancer and Exploration of the Mechanism of Resistance to Immunotherapy nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a PDCD1 binder may also engage these)

ProteinNameSimilarity
Q9NZC2 — 0.972 Q9NZC2 →
Q99NH8 — 0.966 Q99NH8 →
Q7Z692 — 0.964 Q7Z692 →
O18796 — 0.960 O18796 →
Q9Y3P8 — 0.951 Q9Y3P8 →
Q9UGN4 — 0.950 Q9UGN4 →
Q02242 — 0.950 Q02242 →
P09564 — 0.949 P09564 →
Q6BAA4 — 0.948 Q6BAA4 →
Q8IYS5 — 0.947 Q8IYS5 →
Q01113 — 0.947 Q01113 →
Q8C503 — 0.944 Q8C503 →
Q6GTX8 — 0.944 Q6GTX8 →
Q5RF19 — 0.942 Q5RF19 →
Q08708 — 0.942 Q08708 →
Q13477 — 0.941 Q13477 →
A8MVS5 — 0.941 A8MVS5 →
P41155 — 0.940 P41155 →
O95998 — 0.939 O95998 →
Q14626 — 0.939 Q14626 →
P70225 — 0.938 P70225 →
Q64385 — 0.938 Q64385 →
Q99MF4 — 0.938 Q99MF4 →
Q5DRQ8 — 0.937 Q5DRQ8 →
P26842 — 0.937 P26842 →
Q28110 — 0.935 Q28110 →
Q5M869 — 0.935 Q5M869 →
Q6UX52 — 0.935 Q6UX52 →
Q9DCF1 — 0.933 Q9DCF1 →
Q7Z4S9 — 0.933 Q7Z4S9 →